Remedium Lifecare Ltd. engages in trading in API intermediates KSMs & CRMs and various other raw materials used in API manufacturing. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2016-01-12. The firm is engaged in the business of trading application programming interfaces (APIs) intermediates and various other raw materials used in API trading, such as amino isophthalic acid, tellurium (IV) oxide, Grignard reagent, lodine, Selenium Metal Powder, trimethyl sulfoxonium lodide (TMSI). The firm operates through two business verticals: Products and Services. Products business comprises trading and sale of APIs and intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. The firm's products include atorvastatin calcium (amorphous), atorvastatin calcium (crystalline), citalopram hydrochloride, montelukast sodium, and cetirizine dihydrochloride, levocetirizine dihydrochloride, pantoprazole sodium ambroxol hydrochloride, losartan potassium, phenylephrine, phenylephrine hydrochloride, lisinopril dihydrate, and lisinopril.
Loading chart…
Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:
The headline call - descriptive label, conviction, and the synthesis behind it.
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Forensic and governance risk pointers, severity-ranked.
Solvency and earnings-quality score.
Quarter-by-quarter earnings-call briefs - what changed and why.
24 fields couldn't be derived. The company was scraped before the cash-flow and balance-sheet rows were captured. Re-running an analysis will refresh these.